9741x (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
90 | Retinitis pigmentosa | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-019079-32-PT (EUCTR) | 19/05/2010 | 05/04/2010 | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration). | Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9715X INN or Proposed INN: Brimonidine Tartrate Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9742X INN or Proposed INN: Brimonidine Tartrate Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9741X INN or Proposed INN: Brimonidine Tartrate | Allergan Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Portugal;Czech Republic;Germany;Italy;United Kingdom | |||
2 | EUCTR2010-019079-32-DE (EUCTR) | 12/05/2010 | 13/04/2010 | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration). | Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9715X INN or Proposed INN: Brimonidine Tartrate Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9742X INN or Proposed INN: Brimonidine Tartrate Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9741X INN or Proposed INN: Brimonidine Tartrate | Allergan Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Portugal;Czech Republic;Germany;Italy;United Kingdom |